Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age34-80
SponsorVA Office of Research and Development

About this trial

This experimental trial is investigating the use of magnetic stimulation of the brain as a possible treatment for post-stroke fatigue in people who have had a stroke more than six months prior to enrolling. Fatigue is a common condition after a stroke and can negatively impact an individual's ability to perform desired social and physical activities. Magnetic stimulation of the brain has been shown to improve signs and symptoms of related psychological (e.g., depression) conditions. Participants in this trial will receive a type of magnetic stimulation called repetitive transcranial magnetic stimulation, or rTMS. The investigators will measure feelings of fatigue and other clinical characteristics related to mood and cognition before and after participants receive rTMS.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

More than 6 months post-stroke

Clinically present fatigue

Disqualifiers

Contraindications to magnetic resonance imaging (MRI)/transcranial magnetic stimulation (TMS)/repetitive transcranial magnetic stimulation (rTMS), e.g., implanted metal within the head, history of seizures

Inability to follow simple three-step instructions

Diagnosed comorbid neurological conditions (e.g. multiple sclerosis, Parkinson's disease, moderate/severe traumatic brain injury (TBI)

Pregnancy

Trial design

Design model

Parallel

Treatments tested in this trial

  • High frequency repetitive transcranial magnetic stimulation

    Device

    MagVenture MagPro X100 with MagOption

  • Sham repetitive transcranial magnetic stimulation

    Device

    MagVenture MagPro X100 with MagOption

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Real M1 High Frequency rTMSExperimental treatment 1 intervention
Group B: Sham rTMSSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Fatigue Severity Scale (FSS) score

The Fatigue Severity Scale (FSS) is a patient reported outcome measure assessing perceived influence of fatigue over the past week. The scale consists of nine questions measured on a 7-point Likert scale (1-7). The FSS' range of scores is from 9 (min) to 63 (max) with lower numbers representing lower/less impact of fatigue.

Time frame
Change from baseline FSS score to 7 days after last treatment

Secondary outcomes

1

Change in Modified Fatigue Impact Scale (MFIS) score

The Modified Fatigue Impact Scale (MFIS) is a Patient reported outcome assessing the impact of fatigue over the past four weeks. The questionnaire is comprised of 21 questions covering three domains (physical, cognitive, and psychosocial subscales). The assessment is graded on a 5 point Likert scale (0-4). The MFIS' range of scores is from 0-84 with higher scores indicating greater impact/worse fatigue. The range of scores for the physical, cognitive, and psychosocial subscales are 0-36, 0-40, and 0-8 respectively. Greater scores indicate greater/worse impact of fatigue.

Time frame
Change from baseline MFIS score to 7 Days after last treatment
2

Change in Fatigue Severity Scale (FSS) score

The Fatigue Severity Scale (FSS) is a patient reported outcome measure assessing perceived influence of fatigue over the past week. The scale consists of nine questions measured on a 7-point Likert scale (1-7). The FSS' range of scores is from 9 (min) to 63 (max) with lower numbers representing lower/less impact of fatigue.

Time frame
Change from baseline FSS score to 3 months after last treatment
3

Change in Modified Fatigue Impact Scale (MFIS) score

The Modified Fatigue Impact Scale (MFIS) is a Patient reported outcome assessing the impact of fatigue over the past four weeks. The questionnaire is comprised of 21 questions covering three domains (physical, cognitive, and psychosocial subscales). The assessment is graded on a 5 point Likert scale (0-4). The MFIS' range of scores is from 0-84 with higher scores indicating greater impact/worse fatigue. The range of scores for the physical, cognitive, and psychosocial subscales are 0-36, 0-40, and 0-8 respectively. Greater scores indicate greater/worse impact of fatigue.

Time frame
Change from baseline MFIS score to 3 months after last treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

VA Office of Research and Development

Lead sponsor

Joseph Maxwell Cleland VA Medical Center

Collaborator